Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Stroke is a leading cause of death and disability, with high recurrence rates.
• Secondary prevention aims to avert subsequent cerebrovascular and atherosclerotic events.
• Aspirin is a traditional first-line agent, but newer antiplatelet therapies require evaluation.

Purpose of the Study:

• To review existing evidence on antiplatelet agents for secondary stroke prevention.
• To specifically define the role of Aggrenox (aspirin/modified-release dipyridamole) in this context.
• To analyze clinical studies with stroke as a primary or combined outcome.

Main Methods:

• Literature review of clinical studies.
• Focus on antiplatelet therapies, including aspirin and Aggrenox.
• Analysis of studies reporting stroke as a primary or component outcome.

Main Results:

• Evidence for aspirin's role in secondary stroke prevention is established.
• The specific efficacy and safety of Aggrenox in secondary stroke prevention require further definition.
• Comparative data on newer agents versus aspirin is emerging.

Conclusions:

• Aspirin remains a cornerstone of secondary stroke prevention.
• The precise role of Aggrenox in preventing recurrent stroke needs clarification based on comprehensive evidence.
• Further research is warranted to establish optimal antiplatelet strategies.